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To the Editor
Based on their study, “Increased mycophenolic acid exposure in stable kidney transplant recipients on tacrolimus as compared with
, Braun et al. concluded that mycophenolic acid (MPA) exposure is greater inthose on sirolimus: implication for pharmacokinetics ”
tacrolimus treated patients than in those treated with sirolimus during maintenance immunosuppression after kidney transplant and
suggested that it may reflect an intestinal interaction of tacrolimus and MPA ( ).1 
Knowledge of whether MPA exposure is differentially modified by tacrolimus and sirolimus is important because of the current
clinical trend of substituting calcineurin inhibitors for mTOR inhibitors and of the growing evidence that MPA exposure should be
controlled to optimize therapy.
However, given the interindividual pharmacokinetic variability of MPA, we feel that the number of patients studied by Braun et al. (n=
9 on sirolimus 14 on tacrolimus) was too low to rigorously demonstrate a pharmacokinetic interaction. We recently conducted avs 
pharmacogenetic/pharmacokinetic study of MPA in a larger group of kidney transplant recipients and found no difference of MPA and
MPA-glucuronide dose-normalized exposures between patients on sirolimus (n 42) and tacrolimus (n 28), with similar renal function ( )= = 2 
( ).Table 1 
Braun et al. suggested that MPA was better absorbed in the gastrointestinal tract when associated with tacrolimus than with sirolimus
and argued that recent clinical findings from Mino et al. ( ) and experimental data involving an ex-vivo swine intestinal perfusion model (3 
) supported their hypothesis. In fact, in the perfusion model tacrolimus resulted in higher amounts of MPA-glucuronide with no reported4 
change in MPA, which rather suggests that tacrolimus decreases MPA oral bioavailability. Conversely, a well-designed drug interaction
study in rats showed that MPA concentrations during monotherapy are not different from concentrations detected during tacrolimus
coadministration, which is not in favour of an interaction ( ). On the other hand, the study from Milo et al. compared MPA5 
pharmacokinetics between kidney transplant recipients and patients with lupus nephritis receiving no calcineurin inhibitors but high doses
of glucocorticoids, which makes any extrapolation to other situations very hazardous. The alternative hypothesis of unknown‘ ’
protein-protein interaction raised by Braun et al. seems very speculative.
The conclusions drawn by Braun et al. about the interaction between mycophenolate and tacrolimus appear thus to be conflicting with
experimental findings as well as with observations in a larger population. However, the definitive proof can only be brought by a
randomized cross-over clinical pharmacokinetics study in homogenous groups of transplant recipients.
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Table 1
Comparison of mycophenolic acid pharmacokinetics associated with sirolimus and tacrolimus comedication in renal transplant recipients at 3 to 6 months post transplant.
Dose normalized parameter Sirolimus (n 42)= Tacrolimus (n 28)= P
MPA
AUC (mg.h/l)/g0 12h – 64.6 34.7± 66.0 29.7± 0.6401
C (mg/l)/gmax 20.1 9.4± 27.2 21± 0.2674
C (mg/l)/gmin 4.4 3.5± 3.9 2.5± 0.6958
MPA-glucuronide
AUC (mg.h/l)/g0 9h – 1011 595± 1183 611± 0.1220
C (mg/l)/gmax 152 84± 177 95± 0.2059
C (mg/l)/gmin 99 75± 108 59± 0.3436
The pharmacokinetic parameters are shown as mean values SD. AUC, area under the curve; C , peak plasma concentration; C , trough plasma concentration; MPA, mycophenolic acid. Details on± max min 
patient characteristics given in ( ).2 
